Vetoquinol Sa operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vetoquinol Sa with three other
pharmaceutical manufacturers in Europe:
FAES Farma SA
sales of 274.58 million Euro [US$309.91 million]
of which 84%
was Speciality Pharmaceuticals),
(378.10 million Euro [US$426.75 million]
of which 83%
was Therapy), and
Dechra Pharmaceuticals PLC
based in the United Kingdom
(£359.28 million [US$465.99 million]
of which 63%
was European Pharmaceuticals).
During the year ended December of 2017, sales at
Vetoquinol Sa were 352.17 million Euro (US$397.49 million).
a very small
increase of 0.5%
versus 2016, when the company's sales were 350.35 million Euro.
This was the fifth consecutive year of sales increases at Vetoquinol Sa
(and since 2012, sales have increased a total of 18%).
Sales of Asia Pacific (Rest of World) saw an increase
that was more than double the company's growth rate: sales were up
10.3% in 2017, from
30.41 million Euro to 33.55 million Euro.
Vetoquinol Sa also saw significant increases in sales in
Americas (up 2.6% to 122.73 million Euro)
Not all segments of Vetoquinol Sa experienced an increase in sales in 2017:
sales of Europe fell 2.2% to 195.90 million Euro.